On January 14, Shenzhen YHLO Biotech Co., Ltd. released the 2022 annual performance forecast.

Performance forecasts

 

It is expected that the net profit attributable to the owners of the parent company in 2022 will be 1.02 billion CNY to 1.1 billion CNY, an increase of 398.17% to 437.25% year-on-year. Compared with the same period of the previous year, it increased by 815.2524 million CNY to 895.2524 million CNY, an increase of 398.17% to 437.25% year-on-year.

 

It is expected that the net profit attributable to the owners of the parent company in 2022, net of non-recurring profits and losses, will be 9.64 CNY to 1.044 billion CNY, an increase of 782.0435 million CNY to 862.0435 million CNY compared with the same period of the previous year, an increase of 429.80% to 473.76% year-on-year.

 

The main reason for the change in performance for the current period

 

This was mainly due to the increase in sales of the company's non-covid self-produced products business and covid-19 product business during the reporting period.

In the non-COVID self-produced products business, it mainly benefited from the rapid growth of chemiluminescence instrument installation, and sales revenue increased year-on-year due to increased reagent consumption;

 

In terms of COVID product business, the COVID antigen detection kit (colloidal gold method) has achieved sales in China (including Hong Kong and Macao), Europe, Japan and other markets, while the company launched the COVID (2019-nCoV) and influenza A/B virus antigen detection kit (colloidal gold method) during the reporting period and sold it in overseas markets, and the increase in sales revenue of the above related products led to a significant year-on-year increase in the sales revenue of the COVID product business.